Horizon Pharma
AcquiredDublin, Ireland · Founded 2005
- Headquarters
- Dublin
- Employees
- 1001–5000
- Founded
- 2005
- Business Model
- B2B
- Website
- horizontherapeutics.com
About
Horizon Therapeutics (formerly Horizon Pharma) was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Founded in 2005 in Illinois, the company built a portfolio of approved therapies including Tepezza for thyroid eye disease, Krystexxa for refractory gout, and Actimmune, serving patients primarily in the United States. Horizon was acquired by Amgen in October 2023 for approximately $27.8 billion, becoming part of Amgen's rare disease portfolio.
Summary
Horizon Pharma is a Biotech company based in Dublin, Ireland, founded in 2005. Investors include Amgen.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2023
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...